Sight Sciences' analysis shows TearCare can save health plans $36.87 PMPY over traditional dry eye treatments in the U.S. Results from a Budget Impact Analysis indicate that a 20% increase in market ...

Please provide your email address to receive an email when new articles are posted on . More than half of participants experienced improvement in reading speed after one treatment with TearCare.

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this Healio Video Perspective from the AAO meeting, Neel R. Desai, MD, of The Eye Institute of West ...

MENLO PARK, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing ...

Paul Badawi, Co-Founder, President, CEO & Director, reported, "Our strong third quarter results were driven by excellent performance by our Surgical Glaucoma team, where we returned to growth in the ...

Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an ...

The SAHARA trial achieved its primary six-month endpoint, demonstrating the superiority of interventional eyelid procedures enabled by TearCare over Restasis eyedrops in the improvement of tear break ...

The analysis, conducted from a US healthcare payer perspective using a 1-year time horizon, revealed that TearCare resulted in lower per-patient annual costs ($4,916) and higher quality-adjusted life ...